Scarica l'app Stockscreener
58.53
4.39%
2.46
Dopo l'orario di chiusura:
59.76
1.23
+2.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$56.07
Aprire:
$56.61
Volume 24 ore:
1.66M
Relative Volume:
1.63
Capitalizzazione di mercato:
$4.05B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
-14.82
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
+6.15%
1M Prestazione:
+32.45%
6M Prestazione:
+20.61%
1 anno Prestazione:
+9.94%
Intervallo 1D:
$55.87
$59.13
Intervallo di 1 settimana:
$49.46
$59.13
Portata 52W:
$33.19
$61.28
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Confronta MRUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
58.53 | 3.52B | 35.93M | -244.56M | -157.31M | -3.95 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? - Benzinga
Merus, N.V. Provides Updates on Clinical Development - marketscreener.com
Merus NV Stock Skyrockets 8%: Bull Run Intact or Peak Approaching? - Daily Chhattisgarh News
Merus Announces Promising Phase 2 Trial Results - TipRanks
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Merus Showcases Next-Gen Cancer Antibody Platform at Two Premier Healthcare Conferences - Stock Titan
Merus stock holds $85 target, Buy rating at H.C. Wainwright - Investing.com
Merus stock holds $85 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Merus (MRUS) Stock: Analysts Rally Behind Biotech After Cancer Treatment Breakthrough - CoinCentral
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts - Defense World
Lazard Asset Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Price Target Raised to $110.00 - Defense World
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT - Yahoo Finance
Merus N.V.’s SWOT analysis: promising cancer drug pipeline boosts stock outlook - Investing.com Australia
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data - MSN
Merus shares rise as Needham lifts price target to $88 By Investing.com - Investing.com South Africa
Merus stock price target raised to $110 at BMO Capital - Investing.com Australia
Merus stock target holds at $88, Truist affirms Buy rating By Investing.com - Investing.com South Africa
Northern Trust Corp Has $3.21 Million Stake in Merus (NASDAQ:MRUS) - Defense World
Merus stock target holds at $88, Truist affirms Buy rating - Investing.com Australia
Merus shares rise as Needham lifts price target to $88 - Investing.com Australia
Big Gains For Imunon, Merus, And Douglas Elliman - Finimize
Merus stock price target raised to $110 at BMO Capital By Investing.com - Investing.com Nigeria
Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeigen robuste Wirksamkeit und Dauerhaftigkeit bei der Erstlinienbehandlung von PD-L1-positivem r/m HNSCC - GlobeNewswire Inc.
Vorläufige Ergebnisse von Merus zu Petosemtamab mit - GlobeNewswire
Merus (NASDAQ:MRUS) Shares Gap Up After Analyst Upgrade - Defense World
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC - Yahoo Finance
Merus’ ASCO data bolster case for first-in-class bispecific - BioCentury
Merus combo trounces Keytruda in head-and-neck phase II - BioWorld MedTech
Sector Update: Health Care Stocks Decline Late Afternoon - marketscreener.com
Top Midday Gainers - marketscreener.com
MRUS: BMO Capital Raises Price Target for Merus to $110 | MRUS S - GuruFocus
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled By Stocktwits - Investing.com India
MRUS: BMO Capital Raises Price Target for Merus to $110 | MRUS Stock News - GuruFocus
Merus Shares Surge After Revealing Favorable Interim Cancer Trial Data - marketscreener.com
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled - MSN
Merus Bispecific Impresses In Head And Neck Cancer - insights.citeline.com
Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday - Benzinga
Merus (MRUS) Price Target Increased Following Positive Phase 2 R - GuruFocus
Merus (MRUS) Price Target Raised by BMO Capital as Confidence Grows | MRUS Stock News - GuruFocus
Merus (MRUS) Shares Surge on Promising Cancer Drug Trial Results - GuruFocus
Sector Update: Health Care - marketscreener.com
Merus stock gains on cancer drug data (MRUS:NASDAQ) - Seeking Alpha
MRUS: Analyst Raises Price Target for Merus to $88 | MRUS Stock News - GuruFocus
Merus Says Interim Cancer Trial Data Show 'Robust' Efficacy, Durability; Shares Jump Premarket - marketscreener.com
Merus (MRUS) Gains Extended-Session Momentum On Trial News - Stocks Telegraph
Investors Purchase High Volume of Merus Call Options (NASDAQ:MRUS) - Defense World
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):